Coherus Oncology (CHRS) Asset Writedowns and Impairment (2015 - 2025)

Coherus Oncology has disclosed Asset Writedowns and Impairment across 9 years of filings, most recently posting $12.5 million for Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at $12.5 million, up 6.79% year-over-year; the trailing twelve-month figure through Dec 2025 was $24.6 million (up 74.05% YoY), and the FY2025 annual result was $14.1 million, changed 0.3% from the prior year.
• Asset Writedowns and Impairment came in at $12.5 million for Q4 2025 at Coherus Oncology, up from $500000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $48.2 million in Q4 2023 to a low of -$4.3 million in Q2 2024.
• The 5-year median for Asset Writedowns and Impairment is $3.2 million (2023), against an average of $9.6 million.
• Peak annual rise in Asset Writedowns and Impairment reached 109.81% in 2024, while the deepest fall reached 1144.67% in 2024.
• Coherus Oncology's Asset Writedowns and Impairment stood at -$59000.0 in 2021, then soared by 44167.8% to $26.0 million in 2022, then soared by 85.5% to $48.2 million in 2023, then slumped by 75.82% to $11.7 million in 2024, then advanced by 6.79% to $12.5 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $12.5 million (Q4 2025), $500000.0 (Q3 2025), and $11.7 million (Q4 2024), per Business Quant data.